“My most recent MRI showed that there is no tumor,?Canagelo said. “I haven’t had any side effects from the treatment, and I’m getting stronger every day. I would urge patients to seek out second opinions and investigate clinical trials. I can tell you I am so glad I did.?
“Our goal is to change the management of recurrent glioma from a life threatening disease, in which survival rates are typically 25 to 26 weeks, into a chronic disease with extended survival and improved quality of life for patients,?Parsa said. “Although our survival data are encouraging, a larger phase 2 study will be required to determine the benefit of vitespen for patients with recurrent glioma. The consistent, tumor specific immune response seen in these patients suggests that in the right patient population, the vaccine could have a significant impact.?